Brain metastases (BMs) are an important source of morbidity and mortality in patients with metastatic breast cancer (BC). As survival of patients with advanced BC considerably improved thanks to research advancements and new therapeutic approaches, the apparent incidence of BMs is increasing. Local interventions, in the form of either surgical resection or radiation therapy, remain the mainstay in the management of BMs. Systemic treatments are typically used to complement local strategies to further improve and maintain control of central nervous system (CNS) disease. Although high-level evidence data about the impact of the blood–brain barrier (BBB), as well as the efficacy of anti-cancer agents on BMs and differentials between the systemic compartment and CNS are still scant, our understanding of the activity of systemic treatments with impact on BMs is rapidly evolving. Novel anti-HER2 agents, such as tucatinib, ado-trastuzumab emtansine, trastuzumab deruxtecan and neratinib, have shown intracranial efficacy. Current research efforts are ongoing not only to clarify the activity of existing treatments on the CNS, as well as to develop new drugs and innovative multi-modality approaches. This review will encompass the current treatment landscape of BMs arising from BC, with a focus on recent advancements in the field and investigational approaches.

Targeting brain metastases in breast cancer / C. Corti, G. Antonarelli, C. Criscitiello, N.U. Lin, L.A. Carey, J. Cortes, P. Poortmans, G. Curigliano. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 103:(2022 Feb), pp. 102324.1-102324.13. [10.1016/j.ctrv.2021.102324]

Targeting brain metastases in breast cancer

C. Corti;G. Antonarelli
Secondo
;
C. Criscitiello;G. Curigliano
Ultimo
2022

Abstract

Brain metastases (BMs) are an important source of morbidity and mortality in patients with metastatic breast cancer (BC). As survival of patients with advanced BC considerably improved thanks to research advancements and new therapeutic approaches, the apparent incidence of BMs is increasing. Local interventions, in the form of either surgical resection or radiation therapy, remain the mainstay in the management of BMs. Systemic treatments are typically used to complement local strategies to further improve and maintain control of central nervous system (CNS) disease. Although high-level evidence data about the impact of the blood–brain barrier (BBB), as well as the efficacy of anti-cancer agents on BMs and differentials between the systemic compartment and CNS are still scant, our understanding of the activity of systemic treatments with impact on BMs is rapidly evolving. Novel anti-HER2 agents, such as tucatinib, ado-trastuzumab emtansine, trastuzumab deruxtecan and neratinib, have shown intracranial efficacy. Current research efforts are ongoing not only to clarify the activity of existing treatments on the CNS, as well as to develop new drugs and innovative multi-modality approaches. This review will encompass the current treatment landscape of BMs arising from BC, with a focus on recent advancements in the field and investigational approaches.
Brain Metastasis; Breast Cancer; CNS; Nervous System; New Drugs; Radiotherapy; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Immunotherapy; Incidence; Radiosurgery; Tumor Microenvironment
Settore MED/06 - Oncologia Medica
feb-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Brain Mets Corti.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.42 MB
Formato Adobe PDF
2.42 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/910200
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 41
social impact